Families living with Alexander disease have never had a treatment aimed at the disease itself. As of September 3, they do.
The Food and Drug Administration approved Zanvastro, known during development as zilganersen, for children and adults with Alexander disease, a rare and often fatal disorder that damages the brain's white matter. It affects roughly one in one to three million people worldwide, and fewer than 1,000 people in the United States are believed to have it. Until now, care meant managing seizures, feeding problems, and loss of movement as the disease advanced, with nothing to slow the underlying process.
The condition is caused by changes in the GFAP gene, which produces glial fibrillary acidic protein. When that protein accumulates abnormally in astrocytes, the brain's support cells, it damages neurons and myelin and drives progressive decline in movement, speech, swallowing, cognition, and autonomic function. Children with the early-onset form often lose developmental milestones they had already reached.
Zanvastro is an RNA-targeted medicine, an antisense oligonucleotide, designed to reduce production of the abnormal protein before it can build up. It is given as a 50 mg injection into the spinal canal once every three months by a trained clinician.
The Trial Result Behind the Approval
The approval rests on a global, randomized, double-blind study that enrolled 54 participants between the ages of 1.5 and 53 years across 13 sites in eight countries, with participants assigned two-to-one to receive the drug or control for a 60-week treatment period. The primary finding is a form of good news that requires careful reading.
In patients aged five and older receiving the 50 mg dose, walking speed on a standard ten-meter walk test held roughly steady at week 61 while the control group declined, a difference of about 33 percent that reached statistical significance. In practical terms, the drug was not shown to reverse damage in this group. It was shown to hold ground while the disease otherwise took it.
For the youngest children, aged two to four, the pattern looked different. Treated children improved on a standard gross motor function scale while controls declined, a difference that reached nominal significance. That hint that earlier treatment might do more than stabilize is genuinely encouraging and also the least certain part of the dataset, resting on a small group in an ultra-rare disease.
Amy Waldman, MD, the pediatric neurologist at Children's Hospital of Philadelphia who led the study, said the approval "represents a significant advancement in care" for these patients. In a condition where families have watched steady decline as the only trajectory, stability is a meaningful outcome. It is not the same as recovery, and coverage that blurs the two does patients no favors.
The Safety Picture Parents Should Understand
The most common adverse reactions, each occurring in at least a quarter of treated patients and more often than in the control group, were vomiting, back pain, cough, headache and post-lumbar puncture syndrome, the cluster of symptoms that can follow a spinal injection. Serious treatment-emergent adverse events occurred less often in the treated group than in the control group.
More significantly, aseptic meningitis has been reported in treated patients. One patient had a serious reaction of aseptic meningitis that recurred and required a dose interruption and steroid pretreatment. Patients, parents and caregivers are advised to tell their clinician promptly if symptoms consistent with meningitis develop after an injection, including fever, severe headache, neck stiffness, light sensitivity or confusion. That is not a reason to avoid treatment, but it is a reason for families to know what to watch for in the days after each dose. The full prescribing information sets out the warnings in detail.
The quarterly route into the spinal canal also carries practical weight. Each dose is a procedure, not a prescription pickup, requiring a center equipped for the injection and follow-up. For families in rural areas or far from a specialty neurology center, treatment means repeated travel, and access will depend heavily on where care is delivered.
Cost has not been announced. Ionis Pharmaceuticals, which developed the drug, received a rare pediatric disease priority review voucher alongside the approval and says the medicine will reach the United States market in the coming weeks. Therapies in this class have historically carried high annual prices, and insurance coverage decisions for ultra-rare conditions often take time to settle. Ionis has said it will offer patient support services including help with insurance approval, and families should expect prior authorization to be part of the process.
A Diagnosis Problem That Approval Does Not Solve
An approved treatment matters only for patients who have been identified, and Alexander disease is frequently missed or diagnosed late.
The infantile form may be spotted through an enlarged head, developmental delay and characteristic white matter changes on MRI, with genetic testing confirming a GFAP variant. Later-onset and adult forms are harder. Speech and swallowing difficulty, unsteady gait and muscle weakness in adulthood can be attributed to other neurological conditions for years before anyone tests for a leukodystrophy.
If the data on younger children hold up, the value of early diagnosis increases, because starting sooner may matter more than it did when no treatment existed. That places new weight on referral to a neurologist and genetic testing when a child shows unexplained developmental regression alongside abnormal brain imaging.
There is also a practical question about who administers the drug. Alexander disease is managed at a small number of centers with leukodystrophy expertise, and those centers will need to build the capacity to deliver quarterly injections into the spinal canal and monitor for complications. That infrastructure does not appear the day a drug is approved, and early availability is likely to be uneven across the country.
Nothing about this approval should prompt families to change existing care on their own. People already managing Alexander disease should discuss with their neurologist whether they or their child are candidates, what the injection schedule would involve, and what realistic expectations look like.
The approval arrived more than two weeks ahead of its scheduled decision date of September 22. Longer-term data on whether stabilization holds beyond the controlled period, and on how the drug performs in the adult-onset form specifically, will accumulate over the coming years through the study's open-label extension and through use outside a trial setting.
Key Questions Answered
What is Alexander disease? A rare, progressive, and often fatal neurological disorder caused by changes in the GFAP gene. Abnormal protein accumulates in the brain's support cells, damaging white matter and affecting movement, speech, swallowing, and cognition.
Who can receive Zanvastro? The FDA approved it for pediatric and adult patients. The pivotal study enrolled participants between 1.5 and 53 years of age, and the label addresses patients under 2 as well.
Does the drug cure the disease? No. In patients aged five and older it stabilized walking speed over 61 weeks while a control group declined, a difference of about 33 percent. Younger children improved on a motor scale, a finding based on a small group.
How is it given? As a 50 mg injection into the spinal canal once every three months, performed by a trained clinician at a center equipped for the procedure.
What are the main side effects? Vomiting, back pain, cough, headache, and post-lumbar puncture syndrome were most common. Aseptic meningitis has been reported, and meningitis-like symptoms after a dose warrant prompt medical attention.
What will it cost? Pricing has not been announced. Therapies of this type are typically expensive, and families should expect prior authorization and ask the treating center about assistance programs.
What happens next? Longer-term data will show whether stabilization persists beyond the controlled period and how the drug performs in adult-onset disease and across severity levels outside a trial.
